Affimed Announces Annual General Meeting of Shareholders Heidelberg, Germany

Affimed Announces Annual General Meeting of Shareholders

Heidelberg, Germany, May 24, 2022 Affimed N.V. (Nasdaq: AFMD) ( Affimed , or the

Company ), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 Annual General Meeting of Shareholders (the Annual Meeting ) will be held

on June 22, 2022 at 09:00 a.m. CET at the Radisson Blu Hotel, Amsterdam City Center, Rusland 17, 1012 CK Amsterdam, the Netherlands.

agenda of the Annual Meeting are available on Affimed s website at https://www.affimed.com/investors/corporate-governance/ under AGM , as well as the SEC s website at www.sec.gov.

Affimed (Nasdaq: AFMD) is a

clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination

therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE ) molecules, which use patients

immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE . Headquartered in Heidelberg, Germany, with offices in New

York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients lives. For more about the company s people, pipeline and partners, please

visit: www.affimed.com.

Investor Relations Contact

Director, Head of Investor Relations

Tel.: +1 (917) 436-8102